|
Neonatal Intensive Care Drug Manual
|
| bet | 51/654 | | Sana | 03.01.2022 | | Hajmi | 1,5 Mb. | | #14803 |
Amoxicillin Clavulanate
Revision Date : 16-11-2020
|
Approved : TC, KOH
|
Alert
|
Not for intramuscular administration. The pharmacokinetics of clavulanate has not been evaluated in neonates. Dose and frequency are product specific and the products are not interchangeable. 5:1 ratio of amoxicillin and clavulanate used are for intravenous and 4:1 ratios of amoxicillin and clavulanate used for oral administration in neonates.
|
Indication
|
Directed treatment of susceptible bacterial infections covered by amoxicillin but producing beta-lactamase when amoxicillin alone is ineffective; including skin infection, ear infection, sinusitis, urinary tract infection, upper and lower respiratory tract infection, and animal bites. [1,2]
|
Action
|
Semi-synthetic penicillin with similar antibacterial spectrum as ampicillin. It is bactericidal against both, gram-positive and gram-negative bacteria but is destroyed by beta-lactamase produced by many of, these bacteria. Clavulanate binds irreversibly with beta-lactamases produced by a variety of gram-, positive and gram-negative microorganisms and protects amoxicillin from degradation. Thus extending, the spectrum of amoxicillin. [1], Amoxicillin is better -absorbed than ampicillin, following oral administration. [1]
|
Drug Type
|
Antimicrobial agent – Beta-lactam aminopenicillin and Beta-lactamase inhibitor combination
|
Trade Name
|
Oral: Curam 125mg/31.25mg Powder for Suspension,
IV: Amoxiclav Juno 1000/200, Curam 500/100, Curam 1000/200,
|
|
|
| |
